Peroxisome Proliferator-Activated Receptor Ligand

Abstract

An object of the present invention is to provide a peroxisome proliferator-activated receptor γ (PPARγ) ligand derived from a natural product and to provide a composition for prevention or improvement of insulin resistant syndrome, diabetes mellitus, obesity, or visceral fat obesity, characterized by comprising the ligand as an active ingredient. The present invention provides a PPARγ ligand comprising as an active ingredient, at least one compound selected from the group consisting of coumaperine and derivatives thereof. The present invention also provides a composition for prevention or improvement of insulin resistant syndrome, diabetes mellitus, obesity, or visceral fat obesity comprising the compound as an active ingredient.

1 . A peroxisome proliferator-activated receptor γ ligand comprising as an active ingredient, at least one compound selected from the group consisting of coumaperine and derivatives thereof. 
     
     
         2 . The peroxisome proliferator-activated receptor γ ligand according to  claim 1 , wherein the compound is at least one compound selected from the group consisting of N-5-(4-hydroxyphenyl)-2E,4E-pentadienoyl piperidine, N-trans-feruloyl tyramine, N-trans-feruloyl piperidine, N-5-(4-hydroxy-3-methoxyphenyl)-2E,4E-pentadienoyl piperidine, and N-5-(4-hydroxy-3-methoxyphenyl)-2E-pentenoyl piperidine, salts thereof, and esterified forms thereof. 
     
     
         3 . A composition for prevention or treatment of visceral fat obesity comprising as an active ingredient, at least one compound selected from the group consisting of coumaperine and derivatives thereof. 
     
     
         4 . A composition for prevention or treatment of type II diabetes mellitus comprising as an active ingredient, at least one compound selected from the group consisting of coumaperine and derivatives thereof. 
     
     
         5 . A composition for prevention or treatment of insulin resistant syndrome comprising as an active ingredient, at least one compound selected from the group consisting of coumaperine and derivatives thereof. 
     
     
         6 . A composition for prevention or treatment of metabolic syndrome comprising as an active ingredient, at least one compound selected from the group consisting of coumaperine and derivatives thereof. 
     
     
         7 . A composition for prevention or treatment of visceral fat syndrome comprising as an active ingredient, at least one compound selected from the group consisting of coumaperine and derivatives thereof. 
     
     
         8 . The composition according to  claim 3 , wherein the compound is one or more compound(s) selected from the group consisting of N-5-(4-hydroxyphenyl)-2E,4E-pentadienoyl piperidine, N-trans-feruloyl tyramine, N-trans-feruloyl piperidine, N-5-(4-hydroxy-3-methoxyphenyl)-2E,4E-pentadienoyl piperidine, and N-5-(4-hydroxy-3-methoxyphenyl)-2E-pentenoyl piperidine, salts thereof, and esterified forms thereof. 
     
     
         9 . The composition according to  claim 3 , wherein the composition comprises 0.1% by weight to 99% by weight in total of the compound(s) selected from the group consisting of coumaperine and derivatives thereof. 
     
     
         10 . The composition according to  claim 4 , wherein the compound is one or more compound(s) selected from the group consisting of N-5-(4-hydroxyphenyl)-2E,4E-pentadienoyl piperidine, N-trans-feruloyl tyramine, N-trans-feruloyl piperidine, N-5-(4-hydroxy-3-methoxyphenyl)-2E,4E-pentadienoyl piperidine, and N-5-(4-hydroxy-3-methoxyphenyl)-2E-pentenoyl piperidine, salts thereof, and esterified forms thereof. 
     
     
         11 . The composition according to  claim 5 , wherein the compound is one or more compound(s) selected from the group consisting of N-5-(4-hydroxyphenyl)-2E,4E-pentadienoyl piperidine, N-trans-feruloyl tyramine, N-trans-feruloyl piperidine, N-5-(4-hydroxy-3-methoxyphenyl)-2E,4E-pentadienoyl piperidine, and N-5-(4-hydroxy-3-methoxyphenyl)-2E-pentenoyl piperidine, salts thereof, and esterified forms thereof. 
     
     
         12 . The composition according to  claim 6 , wherein the compound is one or more compound(s) selected from the group consisting of N-5-(4-hydroxyphenyl)-2E,4E-pentadienoyl piperidine, N-trans-feruloyl tyramine, N-trans-feruloyl piperidine, N-5-(4-hydroxy-3-methoxyphenyl)-2E,4E-pentadienoyl piperidine, and N-5-(4-hydroxy-3-methoxyphenyl)-2E-pentenoyl piperidine, salts thereof, and esterified forms thereof. 
     
     
         13 . The composition according to  claim 7 , wherein the compound is one or more compound(s) selected from the group consisting of N-5-(4-hydroxyphenyl)-2E,4E-pentadienoyl piperidine, N-trans-feruloyl tyramine, N-trans-feruloyl piperidine, N-5-(4-hydroxy-3-methoxyphenyl)-2E,4E-pentadienoyl piperidine, and N-5-(4-hydroxy-3-methoxyphenyl)-2E-pentenoyl piperidine, salts thereof, and esterified forms thereof. 
     
     
         14 . The composition according to  claim 4 , wherein the composition comprises 0.1% by weight to 99% by weight in total of the compound(s) selected from the group consisting of coumaperine and derivatives thereof. 
     
     
         15 . The composition according to  claim 5 , wherein the composition comprises 0.1% by weight to 99% by weight in total of the compound(s) selected from the group consisting of coumaperine and derivatives thereof. 
     
     
         16 . The composition according to  claim 6 , wherein the composition comprises 0.1% by weight to 99% by weight in total of the compound(s) selected from the group consisting of coumaperine and derivatives thereof. 
     
     
         17 . The composition according to  claim 7 , wherein the composition comprises 0.1% by weight to 99% by weight in total of the compound(s) selected from the group consisting of coumaperine and derivatives thereof.